Senti Biosciences

Update in progress

SNTI (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Senti Biosciences Holdings, Inc. is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform. Its lead product SENTI-202 uses off-the-shelf healthy donor-derived NK cells engineered as CAR-NK cells for oncology, including blood cancers. The company pursues NOT GATE antigen discovery, preclinical solid tumor programs, and partnerships in regenerative medicine. It collaborates with Celest Therapeutics and is based in South San Francisco. Formerly Senti Biosciences, Inc., renamed in 2026. Founded 2016.

Company score

Sentiment: 0.36; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.29; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive